Phase Angle, a Cornerstone of Outcome in Head and Neck Cancer

Daniel Sat-Muñoz 1,2,3,4,* 1, Brenda-Eugenia Martínez-Herrera 5,6,7,10, Javier-Andrés González-Rodríguez 6,8,10, Leonardo-Xicotencatl Gutiérrez-Rodríguez 6,9,10, Benjamín Trujillo-Hernández 7,10, Luis-Aaron Quiroga-Morales 6,11,12, Aldo-Antonio Alcaraz-Wong 4,12, Carlos Dávalos-Cobián 13, Alejandro Solórzano-Meléndez 5,14, Juan-Daniel Flores-Carlos 15, Benjamín Rubio-Jurado 16, Mario Salazar-Páramo 17, Gabriela-Guadalupe Carrillo-Núñez 6,20,21,22 and Luz-Ma-Adriana Balderas-Peña 1,2,6,*

1 Departamento de Morfología, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdG), 950 Sierra Mojada, Puerta 7, Edificio C, 1er Nivel, Guadalajara 44340, Jalisco, Mexico
2 Cuerpo Académico UDG CA-874 “Ciencias Morfológicas en el Diagnóstico y Tratamiento de la Enfermedad”, 950 Sierra Mojada, Puerta 7, Edificio C, 1er Nivel, Guadalajara 44340, Jalisco, Mexico; eduardo.gsanchez@academicos.udg.mx
3 Departamento Clínico de Oncología Quirúrgica, División de Oncología Hematología, Unidad Médica de Alta Especialidad (UMAE), Hospital de Especialidades (HE), Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), 1000 Belisario Domínguez, Guadalajara 44340, Jalisco, Mexico
4 Comité de Cabeza y Cuello, UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 1000 Belisario Domínguez, Guadalajara 44340, Jalisco, Mexico; aldo.alcaraz@imss.gob.mx (A.-A.-A.); dr._solorzano@yahoo.com.mx (A.-M.)
5 Hospital General de Zona (HGZ), #02 c/MF “Dr. Francisco Padrón Puyou”, San Luis Potosí, IMSS, San Luis Potosí 78250, San Luis Potosí, Mexico; bren.mtz16@gmail.com
6 Unidad de Investigación Biomédica 02, UMAE Hospital de Especialidades (HE), Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), 1000 Belisario Domínguez, Guadalajara 44340, Jalisco, Mexico; javier.gonzalez5722@alumnos.udg.mx (J.-A.-G.-R.); xicotencatl.gutierrez@alumno.udg.mx (L.-X.-G.-R.); xicotencatl.gutierrez@hotmail.com (L.-X.-G.-R.); navazava@yahoo.com.mx (A.-H.-N.-Z.)
7 Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad de Colima, Colima 28040, Colima, Mexico; trujillobenjamin@hotmail.com
8 Carrera de Médico Cirujano y Partero, Coordinación de Servicio Social, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdG), Guadalajara 44340, Jalisco, Mexico
9 Carrera de Médico Cirujano y Partero, Coordinación de Servicio Social, Centro Universitario del Sur, Universidad de Guadalajara (UdG), Ciudad Guzmán 49000, Jalisco, Mexico
10 Comisión Interinstitucional de Formación de Recursos Humanos en Salud, Programa Nacional de Servicio Social en Investigación 2021, Demarcación Territorial Miguel Hidalgo 11410, Ciudad de México, México Programa de Doctorado en Investigación Clínica, Coordinación de Posgrado, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdG), Guadalajara 44340, Jalisco, Mexico
11 Unidad Académica de Ciencias de la Salud, Consultor Nutricional en la Clínica de Rehabilitación y Alto Rendimiento ESPORTIVA, Universidad Autónoma de Guadalajara, Zapopan 45129, Jalisco, Mexico
12 Departamento Clínico de Anatomía Patológica, División de Diagnóstico, UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 1000 Belisario Domínguez, Guadalajara 44340, Jalisco, Mexico
13 Departamento Clínico de Gastroenterología, Servicio de Endoscopia, División de Medicina, UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 1000 Belisario Domínguez, Guadalajara 44340, Jalisco, Mexico; endosmedica@gmail.com
14 Departamento Clínico de Oncología Radioterapia, Servicio de Radioterapia, División de Oncología Hematología, UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 1000 Belisario Domínguez, Guadalajara 44340, Jalisco, Mexico
15 Departamento Clínico de Cirugía General, Servicio de Soporte Nutricio, Unidad de Cirugía, UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 1000 Belisario Domínguez, Guadalajara 44340, Jalisco, Mexico; dr_danielflores@hotmail.com

Article

Phase Angle, a Cornerstone of Outcome in Head and Neck Cancer

Received: 28 June 2022
Accepted: 21 July 2022
Published: 24 July 2022
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. License MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Abstract: In patients with head and neck cancer, malnutrition is common. Most cases are treated by chemo-radiotherapy and surgery, with adverse effects on the aerodigestive area. Clinical and biochemical characteristics, health-related quality of life, survival, and risk of death were studied. The selected subjects were divided into normal- and low-phase-angle (PA) groups and followed up for at least two years. Mean ages were 67.2 and 59.3 years for low and normal PA, respectively. Patients with PA < 4.42° had significant differences in age, anthropometric and biochemical indicators of malnutrition, and inflammatory status compared to patients with PA > 4.42°. Statistical differences were found in the functional and symptom scales, with lower functional scores and higher symptom scores in patients with low PA. Median survival was 19.8 months for those with PA < 4.42° versus 34.4 months for those with PA > 4.42° (p < 0.001). The relative risk of death was related to low PA (2.6; p < 0.001). The percentage of living patients (41.7%) is almost the same as the percentage of deceased subjects (43.1%; p = 0.002), with high death rates in patients with PA < 4.42°. Phase angle was the most crucial predictor of survival and a risk factor for death in the studied cases.

Keywords: phase angle; head and neck cancer (H&NC); survival; risk of death

1. Introduction

In patients with head and neck cancer (H&NC), malnutrition is a frequent condition even before treatment, regardless of the anatomical site of the primary tumor (nasal, oral, hypopharynx, and larynx). Most of them are treated by chemo-radiotherapy and surgery; however, these are usually associated with adverse events such as dysphagia, mucositis, nausea, and other aerodigestive symptoms [1–3].

The symptoms associated with the high metabolic rate of this type of tumor contribute to weight loss linked to malnutrition [4], loss of function, and a high rate of adverse outcomes, even with the best treatment, with a high rate of morbidity from complications and mortality [5,6].

Different resources report that in newly diagnosed patients who are naïve to treatment, 3 to 52% show some degree of malnutrition, and during treatment, the percentage increased to 44 to 88% [7].

Bioelectrical impedance analysis (BIA) is a crucial tool used in the clinical setting to assess body composition in different types of patients and allows analysis of not only weight loss but also changes in muscle mass and, through phase angle (PA), the integrity of membranes in cells [8–11]. These are related to functionality, quality of life, and even the risk of complications and mortality [12].
BIA measures the resistance and capacitance of the body and its various tissues by recording a voltage drop across an applied current. The capacitance generates a delay in the voltage relative to the current. The geometric representation of the delay is called the phase angle and represents the angular transformation of the relationship between capacitance and resistance [11–13].

The phase angle represents the resistance generated by body fluids and cell membranes (capacitance) in the human body. It is positively correlated with capacitance and negatively correlated with resistance [14,15]. Healthy people have a phase angle between four and ten degrees [11]. A low phase angle value is linked to cell death or damage to the integrity of cell membranes, and a medium or high value refers to intact cells and the expected amount of water ratio between intracellular and extracellular spaces, which predicts the cell mass of the body [14,15].

Cancer patients, particularly head and neck cancer patients, suffer from malnutrition and loss of lean mass before, during, and after treatment [16]. Therefore, we consider that the phase angle could be a cornerstone for predicting outcome, functionality, response to treatment, and mortality in this specific group of patients.

This report aimed to determine the role of phase angle in the outcomes of head and neck cancer patients in a population with a high prevalence of overweight and obesity.

2. Materials and Methods

This prospective cohort analysis of naïve patients with head and neck cancer followed all of them for at least two years. It was reviewed and approved by the Institutional Review Board of the Instituto Mexicano del Seguro Social 1301. All patients signed an informed consent to participate in the study. The procedures were carried out according to the standards considered in the Declaration of Helsinki.

The EORTC-validated questionnaires for Mexican Spanish QLC-C30 and H&N35 were used to assess health-related quality of life (HRQoL). In total, 120 patients were recruited from a consecutive non-probability sample, aged 30–85 years, with biopsy-confirmed head and neck cancer before initiating multidisciplinary treatment in a tertiary hospital in Guadalajara, México.

Patients with two or more malignant neoplasms, autoimmune illness, chronic lung or renal disease, or any contraindication to perform bioelectrical impedance analysis (metal prostheses or electronic implant devices, limb amputations, or severe edema) were excluded. Patient demographics, clinical stage, anatomical location of the tumor, treatment modality, and laboratory tests were extracted from patient records.

A dietitian validated the body composition analysis and classified the phenotype of the patients as sarcopenia, sarcopenic obesity, obesity, or typical body composition. Before the BIA, patients fasted for 8 h and measurements were performed without jewelry or socks. The SECA 213 height scale (Seca, Germany) was used to measure height. The mBCA SECA 514 bioelectric impedance device (Seca, Germany) determined patients’ weight, phase angle, total skeletal muscle mass, and total body fat percentage, with data used to calculate the body mass index (BMI) and skeletal muscle mass index (SMMI). All of these were used to calculate patient outcomes.

BMI was calculated as described by the World Health Organization. We obtained the SMMI by dividing the total skeletal muscle mass (kg) by the height squared (m²). Based on both measurements, patients were classified into three study groups: (1) non-sarcopenic group (NSG): women SMMI ≥ 6.42 kg/m², men ≥ 8.86 kg/m², and BMI < 25 kg/m²; (2) sarcopenic group (SG): female SMMI < 6.42 kg/m², male < 8.87 kg/m², and a BMI < 25 kg/m²; and (3) sarcopenic obesity group (SOG): women SMMI < 6.42 kg/m², men < 8.87 kg/m², and a BMI ≥ 25 kg/m² [17,18].

The ratio of SMMI to patient weight was used to calculate the proportion of total weight corresponding to muscle mass, normalized by dividing by the square of height. Hand-grip strength was assessed using a Jamar Plus+ Digital hand dynamometer (Patterson Medical Supply, Cedarburg, WI, USA). According to the American Association of Hand
Therapists, patients held the device and compressed it with maximum force to obtain a maximum contraction. The test was repeated three times for each hand, with one-minute rest intervals between measurements. The highest result of all tests was recorded [19].

The EORTC QLQ-C30 v.3, (Brussels, Belgium) questionnaire (validated for Mexican Spanish) was conducted to assess HRQoL. The instrument consists of six multi-item scales (related to patient functioning) and nine single-item scales (describing the severity of cancer-related symptoms). The EORTC QLQ-H&N35 supplementary module for H&NC patients was also used. It consists of 35 questions, 7 multi-item symptom scales, and 11 single-item symptom scales described by the EORTC Scoring Manual [20].

Analysis of the two items of the EORTC questionnaire required linear transformation of each item or multi-item scale to obtain a range of scores from 0 to 100. Higher scores on the functioning scales indicate that patients perceive a better QoL than lower scores. Conversely, higher scores on the symptoms scales indicate a higher frequency of severe symptoms and thus a worse QoL [20].

Statistical analysis was performed with the software package IBM® SPSS® Statistics version 28 (Armonk, NY ®, USA).

Results are presented as means ± standard deviation (SD) for variables with normal distributions. Non-parametric variables were described as medians (interquartile intervals (IQIs)).

Categorical variables were expressed as numbers and percentages of the total. Pearson’s chi-square tests were performed to assess differences between the two groups (Fishers’ tests if the estimated values were <5), and one-way ANOVA and Kruskal–Wallis tests with Bonferroni correction were used to assess differences between the three groups. To determine the relationship, Pearson’s correlation or Spearman’s Rho was calculated depending on the type of variable. Survival analysis was carried out using the Kaplan–Meier method and hazard risk was estimated by Cox regression. Analyses were two-sided, and a p-value < 0.05 was considered significant. Cronbach’s alpha value was used for reliability in the multi-item scales of the EORTC questionnaires.

3. Results

In total, 139 patients with H&NC with a mean age of 63.5 (±13) years, including 32 (23%) women and 107 (77%) men, were studied.

In total, 49 patients without sarcopenia, 52 with sarcopenia, and 38 with sarcopenia obesity were found. The mean phase angle was 4.29° (±0.93; mean CI95% = 4.14° to 4.95°) for the 139 studied patients. According to the sarcopenia phenotype, all three groups showed significant differences between non-sarcopenia and sarcopenia (4.7° (±0.83) versus 4.0° (±0.91); p < 0.001) and non-sarcopenia and sarcopenic-obesity (4.7° (±0.83) versus 4.18° (±0.84); p = 0.023).

Based on the above findings, it was decided to set the cut-off point of the normal phase angle at 4.42°, which coincides with the Youden index of the ROC curve (cut-off point, with the Kolmogorov–Smirnoff (K-S) maximum corresponding to a phase angle of 4.42° and an overall model quality score of 0.55 (sensitivity 0.621; 1-specificity 0.36).

3.1. Characteristics of the Cohort of Head and Neck Cancer Patients

3.1.1. Clinical Aspects

Table 1 describes the results according to a normal (4.42°) or low (<4.42°) phase angle for the studied group of H&NC patients and the clinical characteristic of the studied patients. The table shows that male gender predominates over female (p = 0.035), and the percentage of living patients (41.7%) is almost the same with respect to dead subjects (43.1%; p = 0.002), with high death rates in patients with a phase angle <4.42°.
Table 1. Characteristic of the cohort of head and neck cancer patients studied.

| Clinical Characteristic | Phase Angle < 4.42° n (% Inside Specific Group) | Phase Angle ≥ 4.42° n (% Inside Specific Group) | Total n (% Total Patients) | p Value * |
|-------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------|-----------|
| Gender                  |                                                 |                                                 |                           |           |
| Female                  | 22 (68.8%)                                      | 10 (31.3%)                                      | 32 (100%)                 |           |
| Male                    | 52 (48.6%)                                      | 55 (51.4%)                                      | 107 (100%)                |           |
| Total                   | 74 (53.2%)                                      | 65 (46.8%)                                      | 139 (100%)                | 0.035     |
| Anatomical Location     |                                                 |                                                 |                           |           |
| Oral cavity             | 30 (69.8%)                                      | 13 (30.2%)                                      | 43 (100%)                 |           |
| Larynx                  | 23 (42.6%)                                      | 31 (57.4%)                                      | 54 (100%)                 |           |
| Pharynx                 | 3 (30%)                                         | 7 (70%)                                         | 10 (100%)                 |           |
| Salivary glands         | 3 (50%)                                         | 3 (50%)                                         | 6 (100%)                  |           |
| Nose                    | 8 (53.3%)                                       | 7 (46.6%)                                       | 15 (100%)                 |           |
| Skin                    | 5 (62.5%)                                       | 3 (37.5%)                                       | 8 (100%)                  |           |
| Unknown                 | 1 (100%)                                        | 0 (0%)                                          | 1 (100%)                  |           |
| Others                  | 1 (50%)                                         | 1 (50%)                                         | 2 (100%)                  |           |
| Total                   | 74 (53.2%)                                      | 65 (46.8%)                                      | 139 (100%)                | 0.160     |
| Histology               |                                                 |                                                 |                           |           |
| Squamous or epidermoid  | 65 (52.8%)                                      | 58 (47.2%)                                      | 123 (100%)                |           |
| Others                  | 9 (56.3%)                                       | 7 (43.7%)                                       | 16 (100%)                 |           |
| Total                   | 74 (53.2%)                                      | 65 (46.8%)                                      | 139 (100%)                | 0.506     |
| Clinical Stage          |                                                 |                                                 |                           |           |
| I                       | 10 (45.5%)                                      | 12 (54.5%)                                      | 22 (100%)                 |           |
| II                      | 8 (57.1%)                                       | 6 (42.9%)                                       | 14 (100%)                 |           |
| III                     | 8 (32%)                                         | 17 (68%)                                        | 25 (100%)                 |           |
| IV                      | 40 (63.5%)                                      | 23 (36.5%)                                      | 63 (100%)                 |           |
| Non classified           | 8 (53.3%)                                       | 7 (46.7%)                                       | 16 (100%)                 |           |
| Total                   | 74 (53.2%)                                      | 65 (46.8%)                                      | 139 (100%)                | 0.099     |
| Phenotype by Body Composition |                                               |                                                 |                           |           |
| No Sarcopenia            | 17 (34.7%)                                      | 32 (65.3%)                                      | 49 (100%)                 |           |
| Sarcopenia               | 35 (67.3%)                                      | 17 (32.7%)                                      | 52 (100%)                 |           |
| Sarcopenic obesity       | 22 (57.9%)                                      | 16 (42.1%)                                      | 38 (100%)                 |           |
| Total                   | 74 (53.2%)                                      | 65 (46.8%)                                      | 139 (100%)                | 0.004     |

* Significant p value < 0.05. Chi squared test.

The predominant anatomical locations of H&NC were the larynx and oral cavity, accounting for 69.7% (n = 97) of the cases studied. Squamous/epidermoid histology was predominant (n = 123; 88%). Clinical-stage IV accounted 45% of the cases (n = 63), and 64.7% (n = 90) of the patients had sarcopenia or sarcopenic obesity.

3.1.2. Anthropometrical and Biochemical Indicators

The anthropometric and biochemical parameters revealed significant differences between patients with a low phase angle and those with a normal phase angle in the following parameters: age; hand grip strength; gait speed; BMI (p = 0.042), with a lower BMI but a higher fat percentage in the cases with a lower phase angle; SMMI; hemoglobin; absolute lymphocyte count; serum albumin; and C-reactive protein; all the afore-mentioned parameters are malnutrition and inflammatory indicators (Table 2).
Table 2. Characteristic of the anthropometric and biochemical parameters in the cohort of head and neck cancer patients studied.

| Anthropometrical and Biochemical Indicators | Phase Angle < 4.42° Mean (SD Standard Deviation) | Phase Angle ≥ 4.42° Mean (SD Standard Deviation) | p Value * |
|--------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------|
| Age n = 74                                 | 67.2 (12.32)                                  | 59.3 (12.57)                                  | 0.001     |
| Handgrip strength n = 65                   | 22.6 (8.0)                                    | 31.1 (8.0)                                    | <0.001    |
| Gait speed n = 74                          | 0.75 (0.2)                                    | 0.92 (0.2)                                    | <0.001    |
| Phase angle n = 65                         | 3.6 (0.6)                                     | 5.1 (0.5)                                     | 0.001     |
| Body Mass Index (BMI) n = 74               | 24.9 (6.0)                                    | 26.7 (4.2)                                    | 0.042     |
| Total Fat percentage n = 74                | 33.5 (11.2)                                   | 30.7 (8.9)                                    | <0.057    |
| Skeletal Muscle Mass Index (SMMI) n = 65   | 7.3 (3.4)                                     | 10.1 (5.1)                                    | <0.001    |
| Biochemical Indicators                     |                                               |                                               |           |
| Hemoglobin n = 74                          | 12.6 (1.9)                                    | 13.9 (1.7)                                    | <0.001    |
| Absolute lymphocyte count n = 74           | 1557 (946)                                    | 1920 (1016)                                   | 0.024     |
| Albumin ** n = 65                          | 4.1 (3.6–4.3)                                 | 4.4 (4.15–4.5)                                | <0.001    |
| C-Reactive Protein ** n = 65               | 23.15 (5.8–28.25)                             | 10.4 (2.9–21.3)                               | <0.001    |
| Total cholesterol n = 65                   | 184.2 (50.0)                                  | 183.5 (32.3)                                  | 0.465     |

* Significant p value < 0.05. Student’s T test. ** Significant p value < 0.05. U de Mann–Whitney test. Nonparametric distribution values. Median (interquartile interval).

3.2. Characteristics of the Health-Related Quality of Life in the Head and Neck Cancer Patient Cohort

3.2.1. Results of the EORTC QLQ-C30 Questionnaire

Regarding the health-related quality of life functioning and symptom scales, statistical differences were found in the following scores: global health status/quality of life, physical functioning, role functioning, fatigue, pain, insomnia, and loss of appetite for the EORTC QLQ-C30 questionnaire, with lower scores on the functional scales and higher scores on symptoms in patients with a low phase angle (Table 3).

Table 3. EORTC QLQ-C30 and EORTC QLQ-H&N35 in the studied head and neck cancer patient cohort.

| Scores for the QLQ Scales                  | Phase Angle < 4.42° Mean (SD Standard Deviation) | Phase Angle ≥ 4.42° Mean (SD Standard Deviation) | p Value * |
|--------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------|
| EORTC QLQ-C30 (SCORE 0–100)              |                                               |                                               |           |
| Global Health Status/Quality of Life n = 74| 62.2 (25.7)                                  | 76.4 (21.7)                                  | <0.001    |
| Physic Functioning ** n = 65              | 70 (40–93)                                    | 93.3 (80–100)                                 | <0.001    |
| Role Functioning n = 74                   | 83.3 (33.3–100)                               | 100 (75–100)                                 | 0.003     |
| Emotional Functioning n = 65              | 67.7 (27.9)                                   | 72.4 (27.3)                                  | 0.314     |
| Cognitive Functioning n = 65              | 79.9 (21.0)                                   | 83.9 (20.6)                                  | 0.264     |
| Social Functioning n = 65                 | 71.4 (30.5)                                   | 79.5 (33.0)                                  | 0.135     |
| Fatigue n = 65                             | 47.7 (29.0)                                   | 21.4 (25.47)                                 | <0.001    |
| Nausea and vomiting n = 65                 | 8.3 (17.3)                                    | 10.8 (25.6)                                  | 0.508     |
| Pain ** n = 65                             | 16.7 (0–50)                                   | 0.0 (0–33.3)                                 | 0.009     |
| Dyspnea ** n = 65                          | 0.0 (0–33.3)                                  | 0.0 (0–33.3)                                 | 0.121     |
| Insomnia n = 65                            | 45.5 (39.2)                                   | 31.8 (37.9)                                  | 0.039     |
| Loss of appetite ** n = 65                 | 16.7 (0.0–66.7)                               | 0 (0.0–0.0)                                  | <0.001    |
| Constipation ** n = 65                     | 32 (36.4)                                     | 26.7 (35.5)                                  | 0.386     |
| Diarrhea n = 65                            | 6.3 (14.2)                                    | 6.1 (19.4)                                   | 0.958     |
| Financial Difficulties n = 65              | 40.1 (35.7)                                   | 31.8 (35.1)                                  | 0.171     |
3.2.2. Results of the EORTC QLQ-H&N35 Questionnaire

The EORTC QLQ-H&N35 scales based on the specific symptoms of H&NC patients showed significantly higher scores in patients with a low phase angle for the following items: pain, swallowing, senses problems, trouble with social eating, teeth, opening mouth, dry mouth, sticky saliva, felt ill, pain killers, and nutritional supplements (Table 3).

3.3. Survival Analysis of the Head and Neck Cancer Patient Cohort

Kaplan-Meier and Cox Regression Analysis Results

The percentage of death patients reach 70% in patients with low phase angle and it is 30% in subjects with preserved phase angle (Table 4). Median survival was 19.8 months (95% confidence interval (CI), 15.6 to 24.1 months) in the phase angle <4.42 group (n = 74) and 34.4 months (95% CI, 29.6 to 39.2) in the comparison group (n = 65; phase angle ≥ 4.42: relative risk by Cox’s regression for death, hazard ratio (HR) = 2.6, 95%CI = 1.52 to 4.6; p < 0.001, Figure 1).

Using the sarcopenia/sarcopenic obesity to classify the study subjects, the mean survival was 24 months (95%CI= 23.1 to 31 months) in sarcopenic subjects (n = 90). In the non-sarcopenic group (n = 49), the mean survival was 34.2 months (95%CI = 28.1 to 40.3; p = 0.033).

Table 4. Survival, death, and loss of follow-up.

| Survival Status       | Clinical Characteristic | Phase Angle < 4.42° n (% Inside Specific Group) | Phase Angle ≥ 4.42° n (% Inside Specific Group) | Total n (% Total Patients) | p Value * |
|-----------------------|-------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------|-----------|
| Alive                 | n = 74                  | 22 (37.9%)                                    | 36 (62.1%)                                    | 58 (41.7%)                 |           |
| Death                 | n = 65                  | 42 (70%)                                      | 18 (30%)                                      | 60 (43.1%)                 |           |
| Lost to follow-up     | n = 65                  | 10 (47.6%)                                    | 11 (52.4%)                                    | 21 (15.2%)                 |           |
| Total                 | n = 139                 | 74 (53.2%)                                    | 65 (46.8%)                                    | 139 (100%)                 | 0.002     |

* Significant p value < 0.05. Chi squared T test.
Using the sarcopenia/sarcopenic obesity to classify the study subjects, the mean survival was 24 months (95%CI= 23.1 to 31 months) in sarcopenic subjects (n = 90). In the non-

4. Discussion

Body composition was measured by BIA (bioelectrical impedance analysis), which is a non-invasive, inexpensive, and relatively easy method to perform [21]. PA is a parameter obtained through reactance and resistance [13]. Resistance represents the opposition of a
PA is, therefore, a parameter used for the assessment of both the integrity of cell membranes throughout the body and nutritional status. It has been proposed as a prognostic factor in chronic diseases associated with frailty, physical wear and tear, and acute diseases with a direct influence on the protein reserves of the body [11], such as oncological diseases [23].

PA shows some physiological variations, such as lower values in women than in men, lower values after the age of 60, and changes in different racial groups, with higher values in African descent and Caucasian populations and lower values in Asian and Latino populations [11,24–26]. In our current observations, we found significant differences between genders when estimating the percentage of individuals with low PA (Table 1), with more than 68% of women affected.

Low PA values in chronic diseases and cancer are associated with an adverse prognosis, prolonged hospital stay, and worse survival than normal values [25,27–31]. We found that the same situation is present in the number of deceased subjects with low PA (70%), oral cavity involvement and low PA (69.8%), or the presence of low PA in terminally ill patients (CS IV 63.5%) and the proportion of sarcopenia/sarcopenic obesity among patients related to low PA (63%), coinciding with the findings of Do-Amaral-Paes [30] and Leon-Idougurram [32] in 2018 and 2022, respectively. Our current results reveal the relationship between PA, clinical, biochemistry, PRO (patient-reported outcomes), and survival/death risk in Mexican H&NC subjects with a high prevalence of overweight-obesity [33,34].

Accurate nutritional diagnosis could allow early detection of nutritional risks prior to worsening of HRQoL secondary to complications and death related to impaired nutritional status [29,31–33].

Our results shown in Table 2 coincide with those of the report by Leon-Idougurram and Do-Amaral-Paes, where we found alterations in the anthropometric and nutritional parameters and inflammatory markers in all three groups at the expense of subjects with low PA [30,32]. However, in 2020, some authors, such as Yasui-Yamada, considered the clinical nutritional significance of PA to be ambiguous [24].

It is essential to highlight the role of tumor cachexia and inflammatory mediators such as C-reactive protein, with a significant increase in patients with PA < 4.42° and sarcopenia, and its relationship with a decreased hand grip strength and gait speed and its negative impact on functional markers in this group of patients. Other altered biochemical indicators reflecting malnutrition and its deleterious cellular effect are low hemoglobin, absolute lymphocyte, and albumin levels in blood patients with low PA, as recently described by the Leon-Idougurram group [32].

The evaluation of QoL of patients with H&NC based on the EORTC QLQ-C30 and QLQ-H&N35 instruments is widely used worldwide. One of the first reports demonstrating the reliability and validity of these was published by Sherman AC in 2000 [35], who analyzed a group of 120 outpatients with advanced H&NC in several clinical scenarios: (1) pre-treatment, (2) during the active phase of treatment, (3) 6-month follow-up, and (4) follow-up over 6 months, compared to patients without malignant disease. Their observations provided insight into the psychometric behavior of the instruments and support the results of the subsequent HRQoL assessment with the same questionnaires, whereby we achieved valid psychometric results for the scales used in both instruments.

For the current cohort, we highlighted the impact of a low PA on global health status, and on functional scales such as physical functioning, role functioning, and symptoms including fatigue, pain, insomnia, and loss of appetite, within the EORTC QLQ-C30 (Table 3).

As previously described, malnutrition affects 50% of patients with H&NC [36] and more than 20% are classified as severe [32,37], leading to high rates of treatment complications and poor response, increasing the risk of delayed wound healing, infections, and deleterious effect on HRQoL [32,33,38]. In the specific EORTC QLQ-H&N35 module, the scales mainly affected are pain, swallowing, sense problem, trouble with social eating, teeth,
opening mouth, dry mouth, sticky saliva, felt ill, pain killers, and nutritional supplements, all with higher scores for the low-PA group than the normal-PA group.

The above results allow us to infer that patient-perceived health status (patient-reported outcome) is closely related to measures of functioning such as gait speed and handgrip strength, in parallel to measures of body composition, specifically phase angle.

Davide de Cicco et al., in 2021 [39], observed that HRQoL is severely impaired in subjects with oral cancer. They studied and described how HRQoL became an established practice worldwide, and has a close relationship with survival, satisfaction, and self-perception, considering it as a secondary endpoint of medical interventions in oncology patients.

The group from Sweden led by Axelsson, in 2018 [40], published the value of the phase angle as a prognostic factor in 128 subjects with H&NC, using a slightly higher cut-off than the one used in our current report (5.91° versus 4.42° used by us). These patients did not have a significant risk of death associated with gender, but age over 60 years accounted for a hazard ratio (HR) of 1.030 (95%CI: 1–1.062; \( p = 0.05 \)), performance status as a reflection of functional status below 80 showed an HR of 5.4 (95%CI: 2.77–10.54; \( p < 0.001 \)), weight loss percentage with an HR of 1.06 (95%CI 1.025–1.107; \( p = 0.001 \)), and a normal phase angle represented a risk factor reduction HR:0.47 (95%CI 0.36–0.62; \( p < 0.001 \)), which are results that are similar to our findings. However, our population had a higher percentage of malnutrition, resulting in worse outcomes with a short follow-up (2 years), compared to their 12-year follow-up.

5. Conclusions

The phase angle in this cohort had a lower cut off than that reported by other groups, reflecting the prevalence of malnutrition in our population, which negatively impacts the HRQoL, outcome, and mortality percentage during the first two years of follow-up, and a significant increase in the HR for death. In summary, it is essential in areas with a high prevalence of obesity, where a multidisciplinary and transdisciplinary treatment team need to take actions directed toward the early detection of patients with a high malnourishment risk and perform intense nutritional management to avoid or limit sarcopenia, sarcopenic obesity, or tumor cachexia.

Author Contributions: Conceptualization, D.S.-M., B.-E.M.-H. and L.-M.-A.B.-P.; Data curation, B.-E.M.-H., J.-A.G.-R., B.T.-H., A.-A.A.-W., C.D.-C., A.S.-M., J.-D.F.-C., B.R.-J. and M.S.-P.; Formal analysis, D.S.-M., B.-E.M.-H., L.-X.G.-R., L.-A.Q.-M., A.-A.A.-W., A.S.-M., J.-D.F.-C., B.R.-J., M.S.-P., G.-G.C.-N., E.G.-S., A.-H.N.-Z. and L.-M.-A.B.-P.; Funding acquisition, L.-M.-A.B.-P.; Investigation, C.D.-C.; Methodology, D.S.-M., B.-E.M.-H., L.-X.G.-R., B.T.-H., A.S.-M., J.-D.F.-C. and L.-M.-A.B.-P.; Project administration, D.S.-M., B.-E.M.-H., E.G.-S. and L.-M.-A.B.-P.; Resources, D.S.-M., B.-E.M.-H., A.S.-M., J.-D.F.-C., E.G.-S. and A.-H.N.-Z.; Software, J.-A.G.-R., L.-X.G.-R., B.T.-H., L.-A.Q.-M., M.S.-P. and G.-G.C.-N.; Supervision, D.S.-M. and L.-M.-A.B.-P.; Validation, B.-E.M.-H.; A.S.-M., J.-D.F.-C., Visualization, L.-A.Q.-M., A.-A.A.-W., C.D.-C., B.R.-J., G.-G.C.-N. and A.-H.N.-Z.; Writing—original draft, D.S.-M., J.-A.G.-R., L.-X.G.-R., B.T.-H., A.S.-M., J.-D.F.-C., M.S.-P., A.-H.N.-Z. and L.-M.-A.B.-P.; Writing—review and editing, D.S.-M. and L.-M.-A.B.-P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Universidad de Guadalajara ['Convocatoria Apoyo a la Incorporación de Nuevos Profesores de Tiempo Completo PRODEP SEP 2018, assigned to Professor number UDG PTC 1388] Luz-Ma.-Adriana Balderas-Peña in document: 511-6/18-9169, date 31 July 2018]. All authors supported the APC.

Institutional Review Board Statement: This study was carried out according to the Declaration of Helsinki guidelines and was approved by the Institutional Review Board of the Comité Local de Investigación en Salud 1301, Instituto Mexicano del Seguro Social, México with the project: “Comportamiento de las escalas funcionales de calidad de vida, indicadores de caquexia, leptina sérica y frecuencia del polimorfismo rs12409877 del gen LEPR en pacientes con carcinoma de células escamosas de cabeza y cuello sin sarcopenia versus sarcopenia u obesidad sarcopenica No. R-2019-1301-164”. 
Informed Consent Statement: This study was carried out according to the Declaration of Helsinki guidelines and was approved by the Institutional Review Board of the Comite Local de Investigacion en Salud 1301, Instituto Mexicano del Seguro Social, Mexico.

Data Availability Statement: The datasets generated and/or analyzed during the current study are not publicly available because they are the property of the Instituto Mexicano del Seguro Social. Institutional and federal dispositions restrict unlimited access to personal data, but they are available from the corresponding authors on reasonable request with prior authorization from the institution.

Conflicts of Interest: The authors declare no conflict of interest in the manuscript, including financial, consultational, institutional, and other relationships that might lead to bias or a conflict of interest, and that the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Adkins, D.; Michel, L.; Wildes, T.; Ley, J.; Thorstad, W.; Nussenbaum, B. Cáncer de Cabeza y Cuello. In Manual Washington de Oncología; Wolters Kluwer: Barcelona, Spain, 2016; pp. 217–240.
2. Johnson, N.W.; Amarasinghe, H.K. Epidemiology and Aetiology of Head and Neck Cancers. In Head and Neck Cancer: Multimodality Management; Bernier, J., Ed.; Springer International Publishing: Cham, Switzerland, 2016; pp. 1–57. ISBN 978-3-319-27601-4.
3. Bennardo, L.; Bennardo, F.; Giudice, A.; Passante, M.; Dastoli, S.; Morrone, P.; Provenzano, E.; Patruno, C.; Nistico, S.P. Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far? Curr. Oncol. 2021, 28, 2317–2325. [CrossRef] [PubMed]
4. Fearon, K.; Strasser, F.; Anker, S.D.; Bodeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011, 12, 489–495. [CrossRef]
5. Gupta, D.; Lammersfeld, C.A.; Vashi, P.G.; King, J.; Dahlk, S.L.; Grutsch, J.F.; Lis, C.G. Bioelectrical impedance phase angle as a prognostic indicator in breast cancer. BMC Cancer 2008, 8, 249. [CrossRef] [PubMed]
6. Yu, B.; Park, K.B.; Park, J.Y.; Lee, S.S.; Kwon, O.K.; Chung, H.Y. Bioelectrical Impedance Analysis for Prediction of Early Complications after Gastrectomy in Elderly Patients with Gastric Cancer: The Phase Angle Measured Using Bioelectrical Impedance Analysis. J. Gastric Cancer 2019, 19, 278–289. [CrossRef]
7. Kohli, K.; Corns, R.; Vinnakota, K.; Steiner, P.; Elith, C.; Schellenberg, D.; Kwan, W.; Karvat, A. Bioimpedance Analysis of Head-and-neck Cancer Patients Undergoing Radiotherapy. Curr. Oncol. 2018, 25, 193–199. [CrossRef]
8. Chasen, M.R.; Bhargava, R. A descriptive review of the factors contributing to nutritional compromise in patients with head and neck cancer. Support. Care Cancer 2009, 17, 1345–1351. [CrossRef]
9. Lavigne, C.; Lau, H.; Francis, G.; Culos-Reed, S.N.; Millet, G.Y.; Twomey, R. Neuromuscular function and fatigability in people diagnosed with head and neck cancer before versus after treatment. Eur. J. Appl. Physiol. 2020, 120, 1289–1304. [CrossRef]
10. Yavuzsen, T.; Davis, M.P.; Ranganathan, V.K.; Walsh, D.; Siemionow, V.; Kirkova, J.; Khoshkhabi, D.; Lagman, R.; LeGrand, S.; Yue, G.H. Cancer-Related Fatigue: Central or Peripheral? J. Pain Symptom Manag. 2009, 38, 587–596. [CrossRef]
11. Barbosa-Silva, M.C.G.; Barros, A.J.D.; Wang, J.; Heymsfield, S.B.; Pierson, R.N. Bioelectrical impedance analysis: Population reference values for phase angle by age and sex. Am. J. Clin. Nutr. 2005, 82, 49–52. [CrossRef]
12. Gomes, T.L.N.; Soares, J.D.P.; Borges, T.C.; Pichard, C.; Pimentel, G.D. Phase angle is not associated with fatigue in cancer patients: The hydration impact. Eur. J. Clin. Nutr. 2020, 74, 1369–1373. [CrossRef]
13. Norman, K.; Wirth, R.; Neubauer, M.; Eckardt, R.; Stobäus, N. The Bioimpedance Phase Angle Predicts Low Muscle Strength, Impaired Quality of Life, and Increased Mortality in Old Patients With Cancer. J. Am. Med Dir. Assoc. 2015, 16, 173.e17–173.e22. [CrossRef] [PubMed]
14. Gupta, D.; Lammersfeld, C.A.; Vashi, P.G.; King, J.; Dahlk, S.L.; Grutsch, J.F.; Lis, C.G. Bioelectrical impedance phase angle in clinical practice: Implications for prognosis in stage IIIB and IV non-small cell lung cancer. BMC Cancer 2009, 9, 37. [CrossRef] [PubMed]
15. Selberg, O.; Selberg, D. Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis. Eur. J. Appl. Physiol. 2002, 86, 509–516. [CrossRef]
16. Navigante, A.; Morgado, P.C.; Casbaniens, O.; Delgado, N.L.; Giglio, R.; Peman, M. Relationship between weakness and phase angle in advanced cancer patients with fatigue. Support. Care Cancer 2013, 21, 1685–1690. [CrossRef] [PubMed]
17. Baracos, V.; Arribas, L. Sarcopenic obesity: Hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann. Oncol. 2018, 29, iii–iv. [CrossRef]
18. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.-P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39, 412–423. [CrossRef] [PubMed]
19. Roberts, H.C.; Denison, H.J.; Martin, H.J.; Patel, H.P.; Syddall, H.; Cooper, C.; Sayer, A.A. A review of the measurement of grip strength in clinical and epidemiological studies: Towards a standardised approach. Age Ageing 2011, 40, 423–429. [CrossRef] [PubMed]
12 of 12

20. Fayers, P.M.; Aaronson, N.K.; Bjordal, K.; Groenvold, M.; Curran, D.; Bottomley, A. EORTC QLQ-C30 Scoring Manual: European Organisation for Research and Treatment of Cancer: Brussels, Belgium, 2001.

21. Bçakli, D.H.; Çehreli, R.; Ozveren, A.; Meseri, R.; Uslu, R.; Karabulut, B.; Akçicek, S.F. Evaluation of Sarcopenia, Sarcopenic Obesity, and Phase Angle in Geriatric Gastrointestinal Cancer Patients: Before and after Chemotherapy. Turk. J. Med. Sci. 2019, 49, 583–588. [CrossRef]

22. Norman, K.; Pichard, C.; Lochs, H.; Pirlich, M. Prognostic impact of disease-related malnutrition. Clin. Nutr. Edinb. Scotl. 2008, 27, 5–15. [CrossRef]

23. Schulz, K.-H.; Patra, S.; Spielmann, H.; Klapdor, S.; Schlüter, K.; van Eckert, S. Physical Condition, Nutritional Status, Fatigue, and Quality of Life in Oncological out-Patients. SAGE Open Med. 2017, 5, 205031217743674. [CrossRef]

24. Yasui-Yamada, S.; Oiwa, Y.; Saito, Y.; Aotani, N.; Matsubara, A.; Matsuura, S.; Tanimura, M.; Tani-Suzuki, Y.; Kashihara, H.; Nishi, M.; et al. Impact of phase angle on postoperative prognosis in patients with gastrointestinal and hepatobiliary-pancreatic cancer. Nutrition 2020, 79–80, 110891. [CrossRef]

25. Garlini, L.M.; Alves, F.D.; Ceretta, L.B.; Perry, I.S.; Souza, G.C.; Clausell, N.O. Phase Angle and Mortality: A Systematic Review. Eur. J. Clin. Nutr. 2019, 73, 495–508. [CrossRef] [PubMed]

26. Bosy-Westphal, A.; Danielzik, S.; Dörhöfer, R.-P.; Later, W.; Wiese, S.; Müller, M.J. Phase Angle From Bioelectrical Impedance Analysis: Population Reference Values by Age, Sex, and Body Mass Index. J. Parenter. Enter. Nutr. 2006, 30, 309–316. [CrossRef] [PubMed]

27. Norman, K.; Stobäus, N.; Zocher, D.; Bosy-Westphal, A.; Szramek, A.; Scheufele, R.; Smoliner, C.; Pirlich, M. Cutoff percentiles of bioelectrical phase angle predict functionality, quality of life, and mortality in patients with cancer. Am. J. Clin. Nutr. 2010, 92, 612–619. [CrossRef]

28. Hui, D.; Bansal, S.; Morgado, M.; Dev, R.; Chisholm, G.; Bruera, E. Phase Angle for Prognostication of Survival in Patients with Advanced Cancer: Preliminary Findings. Cancer 2014, 120, 2207–2214. [CrossRef]

29. Paiva, S.I.; Borges, L.R.; Halpern-Silveira, D.; Assunção, M.C.F.; Barros, A.J.D.; Gonzalez, M.C. Standardized phase angle from bioelectrical impedance analysis as prognostic factor for survival in patients with cancer. Support Care Cancer 2011, 19, 187–192. [CrossRef]

30. do Amaral Paes, T.C.; de Oliveira, K.C.C.; de Carvalho Padilha, P.; Peres, W.A.F. Phase angle assessment in critically ill cancer patients: Relationship with the nutritional status, prognostic factors and death. J. Crit. Care 2018, 44, 430–435. [CrossRef]

31. Hui, D.; Moore, J.; Park, M.; Liu, D.; Bruera, E. Phase Angle and the Diagnosis of Impending Death in Patients with Advanced Cancer: Preliminary Findings. Oncologist 2019, 24, e365–e373. [CrossRef]

32. León-Idougourram, S.; Pérez-Gómez, J.M.; Jiménez, C.M.; L-López, F.; García, G.M.; Puertas, M.J.M.; Herman-Sánchez, N.; Alonso-Echague, R.; Contiente, A.C.; Moreno, M.A.G.; et al. Morphofunctional and Molecular Assessment of Nutritional Status in Head and Neck Cancer Patients Undergoing Systemic Treatment: Role of Inflammasome in Clinical Nutrition. Cancers 2022, 14, 494. [CrossRef]

33. Ackerman, D.; Laszlo, M.; Provisor, A.; Yu, A. Nutrition Management for the Head and Neck Cancer Patient. Cancer Treat. Res. 2018, 174, 187–208. [CrossRef]

34. Barquera, S.; Hernández-Barrera, L.; Trejo, B.; Shamah, T.; Campos-Nonato, I.; Rivera-Dommarco, J. Obesidad en México, prevalencia y tendencias en adultos. Ensanut 2018-19. [CrossRef]

35. Sherman, A.C.; Simonton, S.; Adams, D.C.; Vural, E.; Owens, B.; Hanna, E. Assessing Quality of Life in Patients with Head and Neck Cancer: Cross-Validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck Module (QLQ-H&N35). Arch. Otolaryngol. Head Neck Surg. 2000, 126, 459–467. [CrossRef] [PubMed]

36. van Waejenburg, C.; Rasmussen-Conrad, E.; van den Berg, M.; Merkx, M.; van Staveren, W.; van Weel, C.; van Binsbergen, J. Weight Loss in Head and Neck Cancer Patients Little Noticed in General Practice. J. Prim. Health Care 2010, 2, 16–21. [CrossRef] [PubMed]

37. Espósito, M.R.A.; Herrera-Martínez, A.D.; García, G.M.; Calvo, M.E.; Serrano, C.M.B.; Moreno, M.Á.G. Early Nutrition Support Therapy in Patients with Head-Neck Cancer. Nutr. Hosp. 2018, 35, 505–510. [CrossRef]

38. Bossola, M. Nutritional Interventions in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: A Narrative Review. Nutrients 2015, 7, 265–276. [CrossRef]

39. De Cicco, D.; Tartaro, G.; Ciardiello, F.; Fasano, M.; Rauso, R.; Fiore, F.; Spuntarelli, C.; Troiano, A.; Giudice, G.L.; Colella, G. Health-Related Quality of Life in Oral Cancer Patients: Scoping Review and Critical Appraisal of Investigated Determinants. Cancers 2021, 13, 4398. [CrossRef]

40. Axelsson, L.; Silander, E.; Bosaeus, I.; Hammerlid, E. Bioelectrical phase angle at diagnosis as a prognostic factor for survival in advanced head and neck cancer. Eur. Arch. Oto-Rhino-Laryngol. 2018, 275, 2379–2386. [CrossRef]